Core Viewpoint - Garden Biologics (300401.SZ) announced that its wholly-owned subsidiary, Zhejiang Garden Pharmaceutical Co., Ltd., has received the drug registration certificates for "Alpha-Lipoic Acid Tablets" and "Bisoprolol Amlodipine Tablets" from the National Medical Products Administration [1] Group 1 - The "Alpha-Lipoic Acid Tablets" are primarily used for the treatment of diabetic peripheral neuropathy [1] - The "Bisoprolol Amlodipine Tablets" are mainly used for the treatment of hypertension and can be used alone or in combination with other antihypertensive medications [1]

Core Viewpoint - The company has received drug registration certificates for "Alpha-Lipoic Acid Tablets" and "Bisoprolol Amlodipine Tablets" from the National Medical Products Administration, which will enhance its product line and positively impact its development [1] Group 1 - The full subsidiary Zhejiang Huayuan Pharmaceutical Co., Ltd. has been approved for the registration of "Alpha-Lipoic Acid Tablets," which are primarily used for treating diabetic peripheral neuropathy [1] - The "Bisoprolol Amlodipine Tablets" are mainly used for the treatment of hypertension [1] - Obtaining these drug registration certificates will further enrich the company's product line and promote the upgrade of product capabilities [1]

Core Insights - Fuan Pharmaceutical's wholly-owned subsidiary, Yantai Zhichu Pharmaceutical Co., Ltd., has received a drug registration certificate for Alpha-Lipoic Acid Tablets from the National Medical Products Administration [1] - The drug is classified as a Class 3 chemical drug and is available in specifications of 0.2g and 0.6g [1] - The indication for Alpha-Lipoic Acid Tablets is for the treatment of sensory abnormalities caused by diabetic peripheral neuropathy [1] - A total of four companies, including Zhichu Pharmaceutical, have either passed or are deemed to have passed the consistency evaluation for this drug [1]